Abstract
Pityriasis rubra pilaris (PRP) represents a group of rare inflammatory skin disorders. Diagnosis is often challenging, its treatment is mainly empirical and suffers from the lack of controlled trials. PRP shares overlapping clinical and histological features with psoriasis, suggesting a common underlying pathophysiology. Based on this resemblance, a role of the IL23–TH17-axis in PRP was proposed, and several cases of successful treatment of PRP with psoriasis biologics were reported. However, efficacy remains variable and these therapeutic options lack a valid immunopathological rationale.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
